235 related articles for article (PubMed ID: 24333873)
1. Baclofen, a GABAB receptor agonist, enhances ubiquitin-proteasome system functioning and neuronal survival in Huntington's disease model mice.
Kim W; Seo H
Biochem Biophys Res Commun; 2014 Jan; 443(2):706-11. PubMed ID: 24333873
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy by proteasome activator, PA28γ, improves motor coordination and proteasome function in Huntington's disease YAC128 mice.
Jeon J; Kim W; Jang J; Isacson O; Seo H
Neuroscience; 2016 Jun; 324():20-8. PubMed ID: 26944602
[TBL] [Abstract][Full Text] [Related]
3. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
4. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model.
Wu J; Ryskamp DA; Liang X; Egorova P; Zakharova O; Hung G; Bezprozvanny I
J Neurosci; 2016 Jan; 36(1):125-41. PubMed ID: 26740655
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease.
Hunter JM; Lesort M; Johnson GV
J Neurosci Res; 2007 Jun; 85(8):1774-88. PubMed ID: 17455294
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.
Tang TS; Chen X; Liu J; Bezprozvanny I
J Neurosci; 2007 Jul; 27(30):7899-910. PubMed ID: 17652581
[TBL] [Abstract][Full Text] [Related]
8. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.
Schmidt ME; Buren C; Mackay JP; Cheung D; Dal Cengio L; Raymond LA; Hayden MR
BMC Biol; 2018 Jun; 16(1):58. PubMed ID: 29945611
[TBL] [Abstract][Full Text] [Related]
9. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
[TBL] [Abstract][Full Text] [Related]
10. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model.
Chen X; Wu J; Lvovskaya S; Herndon E; Supnet C; Bezprozvanny I
Mol Neurodegener; 2011 Nov; 6():81. PubMed ID: 22118545
[TBL] [Abstract][Full Text] [Related]
11. p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease.
Park KHJ; Franciosi S; Parrant K; Lu G; Leavitt BR
Neuroscience; 2017 Jun; 352():79-87. PubMed ID: 28391013
[TBL] [Abstract][Full Text] [Related]
12. Synaptic scaling up in medium spiny neurons of aged BACHD mice: A slow-progression model of Huntington's disease.
Rocher AB; Gubellini P; Merienne N; Boussicault L; Petit F; Gipchtein P; Jan C; Hantraye P; Brouillet E; Bonvento G
Neurobiol Dis; 2016 Feb; 86():131-9. PubMed ID: 26626081
[TBL] [Abstract][Full Text] [Related]
13. AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease.
Alto LT; Chen X; Ruhn KA; Treviño I; Tansey MG
PLoS One; 2014; 9(5):e96544. PubMed ID: 24824433
[TBL] [Abstract][Full Text] [Related]
14. Proteasome activator enhances survival of Huntington's disease neuronal model cells.
Seo H; Sonntag KC; Kim W; Cattaneo E; Isacson O
PLoS One; 2007 Feb; 2(2):e238. PubMed ID: 17327906
[TBL] [Abstract][Full Text] [Related]
15. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
Palazuelos J; Aguado T; Pazos MR; Julien B; Carrasco C; Resel E; Sagredo O; Benito C; Romero J; Azcoitia I; Fernández-Ruiz J; Guzmán M; Galve-Roperh I
Brain; 2009 Nov; 132(Pt 11):3152-64. PubMed ID: 19805493
[TBL] [Abstract][Full Text] [Related]
16. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.
Ma Q; Yang J; Li T; Milner TA; Hempstead BL
Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324
[TBL] [Abstract][Full Text] [Related]
17. Neural stem cells derived from the developing forebrain of YAC128 mice exhibit pathological features of Huntington's disease.
Li E; Park HR; Hong CP; Kim Y; Choi J; Lee S; Park HJ; Lee B; Kim TA; Kim SJ; Kim HS; Song J
Cell Prolif; 2020 Oct; 53(10):e12893. PubMed ID: 32865873
[TBL] [Abstract][Full Text] [Related]
18. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease.
Martín-Aparicio E; Yamamoto A; Hernández F; Hen R; Avila J; Lucas JJ
J Neurosci; 2001 Nov; 21(22):8772-81. PubMed ID: 11698589
[TBL] [Abstract][Full Text] [Related]
19. Sigma-1 receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington's disease.
Miki Y; Tanji K; Mori F; Wakabayashi K
Neurobiol Dis; 2015 Feb; 74():25-31. PubMed ID: 25449906
[TBL] [Abstract][Full Text] [Related]
20. Cell-Autonomous and Non-cell-Autonomous Pathogenic Mechanisms in Huntington's Disease: Insights from In Vitro and In Vivo Models.
Creus-Muncunill J; Ehrlich ME
Neurotherapeutics; 2019 Oct; 16(4):957-978. PubMed ID: 31529216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
